Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mesothelioma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Stomach Neoplasms 14 Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 6 Neoplasm Metastasis 5 Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Hepatocellular 3 Adenocarcinoma 3 Thymoma 2 Rectal Neoplasms 2 Non-small Cell Lung Cancer Metastatic 2 Malignant Solid Tumor 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Metastatic Small Intestinal Adenocarcinoma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Melanoma 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 HER2-positive Gastric Cancer 1

Interventions

Pemetrexed 10 Gemcitabine 8 Cisplatin 8 Nivolumab 4 Carboplatin 4 niraparib 3 durvalumab 3 Vinorelbine 3 Ipilimumab 3 Bevacizumab 3 tremelimumab 2 pembrolizumab 2 olaparib 2 anetumab ravtansine 2 Radiotherapy, Intensity-Modulated 2 Imatinib Mesylate 2 Fluorodeoxyglucose F18 2 vandetanib 1 tazemetostat 1 sargramostim 1 ribociclib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 defactinib 1 decitabine and cedazuridine drug combination 1 bintrafusp alfa protein, human 1 Zoledronic Acid 1 Vitamin B 12 1 Valproic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03560973 2025-03-13

RAMES

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡